penpulimab
Selected indexed studies
- Penpulimab: First Approval. (Drugs, 2021) [PMID:34813051]
- Penpulimab. (, 2006) [PMID:32816421]
- First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. (Lancet Respir Med, 2024) [PMID:38309287]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Penpulimab: First Approval. (2021) pubmed
- Penpulimab. (2006) pubmed
- First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. (2024) pubmed
- Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial. (2025) pubmed
- Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study. (2024) pubmed
- First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial. (2024) pubmed
- Penpulimab and anlotinib in an elderly patient with recurrent cervical cancer: a case report and literature review. (2023) pubmed
- Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer. (2026) pubmed
- Penpulimab in an adolescent patient with pancreatic neuroendocrine carcinoma with liver metastasis: A case report and literature review. (2025) pubmed
- Penpulimab (Anniko) for nasopharyngeal carcinoma. (2025) pubmed